Anti-IL5

Question 1

Mechanism of action

Answer 1

Blocks binding of IL-5 to the alpha chain of the IL-5 receptor complex, which results in reduced production and survival of eosinophils

Question 2

Mepolizumab brand name

Answer 2

Nucala

Question 3

Mepolizumab dosage form

Answer 3

auto-injector

Question 4

Mepolizumab age range

Answer 4

6 and up

Question 5

Mepolizumab AE and clinical pearls

Answer 5

AE: headache, injection site reactions arthralgias, thrombocytopenia, pharyngitis, sinusitis, upper respiratory tract infections
Boxed warning: anaphylaxis
Do not give more than 150 mg per injection site
Monitor for anaphylaxis before and after injection
Indicated for add-on maintenance treatment of patients with severe asthma with an eosinophilic phenotype

Question 6

Reslizumab brand name

Answer 6

Cinqair

Question 7

Reslizumab dosage form

Answer 7

injection

Question 8

Reslizumab age range

Answer 8

18 and up

Question 9

Reslizumab AE and Clinical Pearls

Answer 9

AE: injection site reactions, myalgias, increased creatinine phosphokinase
Boxed warning: anaphylaxis, malignancies
Monitor for anaphylaxis before and after injection
Indicated for add-on maintenance treatment of patients with severe asthma with an eosinophilic phenotype

Question 10

Benralizumab dosage forms

Answer 10

Auto-injector and pre-filled syringe

Question 11

Benralizumab age range

Answer 11

12 and up

Question 12

Benralizumab AE and Clinical Pearls

Answer 12

AE: injection site reactions, antibody development, headache, pharyngitis, fever
Precaution: Anaphylaxis
Available as an in-clinic or at-home injection
Indicated for add-on maintenance treatment of severe asthma in adults and children >12 years of age with an eosinophilic phenotype
Acts on IL-5 receptors while others act on IL-5

Question 13

Benralizumab brand name

Answer 13

Fasenra